Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors
Abstract
This project concerns anastellin, a fragment of fibronectin that inhibits angiogenesis, tumor growth, and metastasis in vivo. It also concerns anginex, synthetic peptide with anti-angiogenic and anti-tumor effects. We have found that anginex resembles anastellin in several biochemical aspects, and that anginex, like anastellin, depends on circulating plasma fibronectin to be active in vivo. We have also found that anginex and anastellin in complex with fibronectin home to angigenic vasculature. It is possible that the fibronectin RGD sequence may function as the homing sequence of the peptide-fibronectin complexes to angiogenic endothelium in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA427128
Entities
People
- Maria Akerman
Organizations
- Sanford Burnham Prebys Medical Discovery Institute